scispace - formally typeset
D

Daniela Galimberti

Researcher at University of Milan

Publications -  563
Citations -  34760

Daniela Galimberti is an academic researcher from University of Milan. The author has contributed to research in topics: Frontotemporal dementia & Dementia. The author has an hindex of 72, co-authored 495 publications receiving 28411 citations. Previous affiliations of Daniela Galimberti include Washington University in St. Louis & University of Siena.

Papers
More filters
Journal ArticleDOI

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

Jean-Charles Lambert, +215 more
- 01 Dec 2013 - 
TL;DR: In addition to the APOE locus (encoding apolipoprotein E), 19 loci reached genome-wide significance (P < 5 × 10−8) in the combined stage 1 and stage 2 analysis, of which 11 are newly associated with Alzheimer's disease.
Journal ArticleDOI

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Stephen Sawcer, +265 more
- 10 Aug 2011 - 
TL;DR: In this article, a collaborative GWAS involving 9,772 cases of European descent collected by 23 research groups working in 15 different countries, they have replicated almost all of the previously suggested associations and identified at least a further 29 novel susceptibility loci.
Journal ArticleDOI

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.

Paul Hollingworth, +177 more
- 01 May 2011 - 
TL;DR: Meta-analyses of all data provided compelling evidence that ABCA7 and the MS4A gene cluster are new Alzheimer's disease susceptibility loci and independent evidence for association for three loci reported by the ADGC, which, when combined, showed genome-wide significance.
Journal ArticleDOI

Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease.

Valentina Escott-Price, +194 more
- 12 Jun 2014 - 
TL;DR: The additional genes identified in this study, have an array of functions previously implicated in Alzheimer's disease, including aspects of energy metabolism, protein degradation and the immune system and add further weight to these pathways as potential therapeutic targets in Alzheimers disease.